Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma

被引：1
|
作者：
Mistry, Kavita [1 ,2 ]
Zhao, Sophia [3 ]
Strohbehn, Ian [4 ]
Wang, Qiyu [4 ]
Hanna, Paul [4 ,5 ]
Strohbehn, Samuel [4 ]
Katz-Agranov, Nurit [4 ]
Sullivan, Ryan J. [6 ]
Sise, Meghan E. [4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA USA
[3] Analyt Now LLC, Brookline, MA USA
[4] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA
[5] Med Coll Wisconsin, Dept Med, Div Nephrol, Milwaukee, WI USA
[6] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷 / 06期
关键词：
METASTATIC MELANOMA; DOUBLE-BLIND; OPEN-LABEL; VEMURAFENIB; PHASE-3; MULTICENTER; DABRAFENIB; TRAMETINIB; PLACEBO; ENCORAFENIB;
D O I：
10.1093/ndt/gfae049
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
10.1093/ndt/gfae049 Video Watch the video of this contribution at https://academic.oup.com/ndt/pages/author_videos gfae049Media1 6348384678112
引用
收藏
页码：1040 / 1043
页数：4
相关论文
共 50 条
  • [21] The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
    Moriah H. Nissan
    David B. Solit
    Current Oncology Reports, 2011, 13 : 479 - 487
  • [22] Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors
    Galus, Lukasz
    Kolenda, Tomasz
    Michalak, Michal
    Mackiewicz, Jacek
    HELIYON, 2024, 10 (07)
  • [23] BRAF/MEK inhibition in melanoma patients with rare BRAF mutations
    Hassel, Jessica Cecile
    Menzer, Christian
    Menzies, Alexander M.
    Carlino, Matteo S.
    Long, Georgina V.
    Kefford, Richard
    Eigentler, Thomas K.
    Johnson, Douglas Buckner
    Schlaak, Max
    Meiss, Frank
    Schilling, Bastian
    Gutzmer, Ralf
    Pfoehler, Claudia
    Meier, Friedegund Elke
    Zimmer, Lisa
    Haalck, Thomas
    Thoms, Kai
    Kopp-Schneider, Annette
    Enk, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Patient with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (02): : 100 - 103
  • [25] Combined inhibition of BRAF and MEK in melanoma patients
    Infante, Jeffrey R.
    Swanton, Charles
    LANCET ONCOLOGY, 2014, 15 (09): : 908 - 910
  • [26] BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management
    Livingstone, Elisabeth
    Zimmer, Lisa
    Vaubel, Julia
    Schadendorf, Dirk
    CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)
  • [27] Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma
    Ziogas, Dimitrios C.
    Konstantinou, Frosso
    Bouros, Spyros
    Theochari, Maria
    Gogas, Helen
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (03) : 301 - 314
  • [28] Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors
    Glass, Lora R. Dagi
    Lawrence, Donald P.
    Jakobiec, Frederick A.
    Freitag, Suzanne K.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2017, 33 (05): : E114 - E116
  • [29] Safety profile: immunotherapy and Braf/Mek inhibitors in metastasic melanoma
    Casas Hidalgo, I.
    Nieto Gomez, P.
    Rodriguez Delgado, A.
    Alvarez Sanchez, R.
    Rodriguez Gomez, P.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 367 - 368
  • [30] Dosing of BRAF and MEK Inhibitors in Melanoma: No Point in Taking a Break
    Lee, Jenny H.
    Carlino, Matteo S.
    Rizos, Helen
    CANCER CELL, 2020, 38 (06) : 779 - 781
12345